Association of lipid-lowering agent use and dry eye disease: A nationwide matched case–control study in Taiwan, 2002–2016

IF 3 3区医学 Q1 OPHTHALMOLOGY Acta Ophthalmologica Pub Date : 2023-03-20 DOI:10.1111/aos.15656

Li-Nien Chien, Yun-I Chou, Yuan-Jen Tsai, Li-Chin Sung, Hung-Yi Liu, Meng-Yin Lin, Tsung-Jen Wang, I-Chan Lin

{"title":"Association of lipid-lowering agent use and dry eye disease: A nationwide matched case–control study in Taiwan, 2002–2016","authors":"Li-Nien Chien, Yun-I Chou, Yuan-Jen Tsai, Li-Chin Sung, Hung-Yi Liu, Meng-Yin Lin, Tsung-Jen Wang, I-Chan Lin","doi":"10.1111/aos.15656","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>The purpose of this study is to evaluate the association between lipid-lowering agent use and the risks of diagnosed dry eye disease (DED).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective, case–control study included 780 786 patients who received lipid-lowering agents in 2002–2016, of which 17 409 were newly diagnosed with DED during a ≥2-year follow-up period. These patients were matched 1:4 with control participants for age, sex, and comorbidities. Separate odds ratios (OR) were calculated for DED and each of statin and fibrate use.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Statin users had significantly higher odds of DED (adjusted OR = 1.12; 95% confidence interval (CI) = 1.08–1.16, <i>p</i> < 0.0001) than nonusers. Fibrate users did not show higher odds of DED than nonusers (adjusted OR = 1.04; 95% CI = 0.99–1.10, <i>p</i> = 0.125). The lipophilic statin users did not show higher odds of DED compared with the hydrophilic statin users (adjusted OR = 0.99, 95% CI = 0.93–1.06, <i>p</i> = 0.729). Among statin users, the odds of DED did not differ significantly between patients receiving statin therapy for >180 days vs. ≤90 days or patients receiving statin therapy for 91–180 days vs. ≤90 days (adjusted OR = 1.00, <i>p</i> = 0.922; adjusted OR = 0.94, <i>p</i> = 0.541, respectively). The odds of DED were not statistically different among patients receiving low-intensity, moderate-intensity, and high-intensity of statin therapy.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Patients receiving statin therapy had a higher DED risk than patients not receiving statin therapy. The type of statin, the duration, and the intensity of statin use were not significantly associated with DED risks. Further studies are required to identify the relevant factors related to DED risks with statin.</p>\n </section>\n </div>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":"101 7","pages":"729-736"},"PeriodicalIF":3.0000,"publicationDate":"2023-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aos.15656","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

The purpose of this study is to evaluate the association between lipid-lowering agent use and the risks of diagnosed dry eye disease (DED).

Methods

This retrospective, case–control study included 780 786 patients who received lipid-lowering agents in 2002–2016, of which 17 409 were newly diagnosed with DED during a ≥2-year follow-up period. These patients were matched 1:4 with control participants for age, sex, and comorbidities. Separate odds ratios (OR) were calculated for DED and each of statin and fibrate use.

Results

Statin users had significantly higher odds of DED (adjusted OR = 1.12; 95% confidence interval (CI) = 1.08–1.16, p < 0.0001) than nonusers. Fibrate users did not show higher odds of DED than nonusers (adjusted OR = 1.04; 95% CI = 0.99–1.10, p = 0.125). The lipophilic statin users did not show higher odds of DED compared with the hydrophilic statin users (adjusted OR = 0.99, 95% CI = 0.93–1.06, p = 0.729). Among statin users, the odds of DED did not differ significantly between patients receiving statin therapy for >180 days vs. ≤90 days or patients receiving statin therapy for 91–180 days vs. ≤90 days (adjusted OR = 1.00, p = 0.922; adjusted OR = 0.94, p = 0.541, respectively). The odds of DED were not statistically different among patients receiving low-intensity, moderate-intensity, and high-intensity of statin therapy.

Conclusions

Patients receiving statin therapy had a higher DED risk than patients not receiving statin therapy. The type of statin, the duration, and the intensity of statin use were not significantly associated with DED risks. Further studies are required to identify the relevant factors related to DED risks with statin.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

降脂药物使用与干眼症的关系：台湾全国匹配病例对照研究，2002-2016。

目的：本研究的目的是评估降脂药物的使用与诊断为干眼病（DED）的风险之间的关系 2002-2016年接受降脂药物治疗的786名患者，其中17名 409例在≥2年的随访期内被新诊断为DED。这些患者与对照组参与者在年龄、性别和合并症方面进行了1:4的匹配。分别计算DED、他汀类药物和贝特类药物的比值比（OR）。结果：他汀类药物使用者发生DED的几率显著较高（校正OR=1.12；95%置信区间（CI）=1.08-1.16，p 180 天与≤90 91-180接受他汀类药物治疗的天数或患者天与≤90 天（调整后OR=1.00，p=0.922；调整后OR=0.94，p=0.541）。在接受低强度、中等强度和高强度他汀类药物治疗的患者中，DED的发生率没有统计学差异。结论：接受他汀类药物治疗的患者比未接受他汀类治疗的患者有更高的DED风险。他汀类药物的类型、使用时间和强度与DED风险无显著相关性。需要进一步的研究来确定与他汀类药物DED风险相关的相关因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Acta Ophthalmologica 医学-眼科学

CiteScore

7.60

自引率

5.90%

发文量

433

审稿时长

6 months

期刊介绍： Acta Ophthalmologica is published on behalf of the Acta Ophthalmologica Scandinavica Foundation and is the official scientific publication of the following societies: The Danish Ophthalmological Society, The Finnish Ophthalmological Society, The Icelandic Ophthalmological Society, The Norwegian Ophthalmological Society and The Swedish Ophthalmological Society, and also the European Association for Vision and Eye Research (EVER). Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.